Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: A randomized, placebo-controlled trial

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 3, 2014, Pages 390-396

  Gonzales, D ^a   Hajek, P ^b   Pliamm, L ^c   Nackaerts, K ^d   Tseng, L J ^e   McRae, T D ^e   Treadow, J ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ADULT; AGITATION; ANKLE FRACTURE; ARTICLE; AUSTRALIA; BELGIUM; CANADA; CONSTIPATION; CONTROLLED STUDY; CZECH REPUBLIC; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; FRANCE; GERMANY; HEADACHE; HUMAN; INSOMNIA; INTERVERTEBRAL DISK HERNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; PATIENT COUNSELING; PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; RHINOPHARYNGITIS; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; THORAX PAIN; TREATMENT DURATION; UNITED KINGDOM; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AUSTRALIA; BENZAZEPINES; CANADA; CHI-SQUARE DISTRIBUTION; COUNSELING; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; ODDS RATIO; QUINOXALINES; RECURRENCE; RETREATMENT; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE DISORDER; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84907873231     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.124     Document Type: Article

References (39)

1. World Health Organization. Tobacco. Fact Sheet no. 339. (2013). Accessed 24 October 2013.
2. Joseph, A.M. et al. Chronic disease management for tobacco dependence: A randomized, controlled trial. Arch. Intern. Med. 171, 1894-1900 (2011).
3. Ockene, J.K. et al. Relapse and maintenance issues for smoking cessation. Health Psychol. 19, 17-31 (2000).
4. Partos, T.R., Borland, R., Yong, H.H., Hyland, A. & Cummings, K.M. The quitting rollercoaster: How recent quitting history affects future cessation outcomes (data from the International Tobacco Control 4-country cohort study). Nicotine Tob. Res. 15, 1578-1587 (2013).
5. Ellerbeck, E.F. et al. Effect of varying levels of disease management on smoking cessation: A randomized trial. Ann. Intern. Med. 150, 437-446 (2009).
6. Fiore, M.C. et al. Clinical Practice Guideline. Treating Tobacco Use and Dependence: 2008 Update. (2008). Accessed 24 October 2013.
7. Agboola, S., McNeill, A., Coleman, T. & Leonardi Bee, J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 105, 1362-1380 (2010).
8. European Medicines Agency. Guideline on the Development of Medicinal Products for the Treatment of Smoking (Doc. Ref. CHMP/EWP/369963/05). (2008). Accessed 24 October 2013.
9. National Institute for Health and Clinical Excellence. Smoking Cessation Services. NICE Public Health Guidance 10. (2008). Accessed 24 October 2013.
10. Zwar, N. et al. Supporting Smoking Cessation: A Guide for Health Professionals. (2011). Accessed 24 October 2013.
11. Department of Health and Human Services, Food and Drug Administration. Report to Congress. Innovative Products and Treatments to Achieve Abstinence From Tobacco Use, Reductions in Consumption of Tobacco, and Reductions in the Harm Associated With Continued Tobacco Use. (2013). Accessed 24 October 2013.
12. Shiffman, S., Dresler, C.M. & Rohay, J.M. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99, 83-92 (2004).
13. Tønnesen, P., Mikkelsen, K., Nørregaard, J. & Jørgensen, S. Recycling of hardcore smokers with nicotine nasal spray. Eur. Respir. J. 9, 1619-1623 (1996).
14. Durcan, M.J. et al. Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am. J. Health Behav. 26, 213-220 (2002).
15. Gourlay, S.G., Forbes, A., Marriner, T., Pethica, D. & McNeil, J.J. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ 311, 363-366 (1995).
16. Hughes, J.R., Grass, J.A. & Pillitteri, J.L. Treatment resistant smokers: A pilot study of nicotine nasal spray and inhaler. J. Addict. Dis. 19, 95-100 (2000).
17. Tønnesen, P., Nørregaard, J., Säwe, U. & Simonsen, K. Recycling with nicotine patches in smoking cessation. Addiction 88, 533-539 (1993).
18. Gonzales, D.H. et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study. Clin. Pharmacol. Ther. 69, 438-444 (2001).
19. Cupertino, A.P., Wick, J.A., Richter, K.P., Mussulman, L., Nazir, N. & Ellerbeck, E.F. The impact of repeated cycles of pharmacotherapy on smoking cessation: A longitudinal cohort study. Arch. Intern. Med. 169, 1928-1930 (2009).
20. Fagerström, K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob. Res. 14, 75-78 (2012).
21. Posner, K., Oquendo, M.A., Gould, M., Stanley, B. & Davies, M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am. J. Psychiatry 164, 1035-1043 (2007).
22. Pfizer. CHANTIX® (Varenicline) Tablets. (2013). Accessed 24 October 2013.
23. Gonzales, D. et al.; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296, 47-55 (2006).
24. Jorenby, D.E. et al.; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296, 56-63 (2006).
25. Anthenelli, R.M. et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: A randomized trial. Ann. Intern. Med. 159, 390-400 (2013).
26. Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T. & Reeves, K.R. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebocontrolled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin. Ther. 29, 1040-1056 (2007).
27. Rennard, S. et al.; Flexible Quit Date Study Group. A randomized placebocontrolled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob. Res. 14, 343-350 (2012).
28. Rigotti, N.A., Pipe, A.L., Benowitz, N.L., Arteaga, C., Garza, D. & Tonstad, S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 121, 221-229 (2010).
29. Tashkin, D.P., Rennard, S., Hays, J.T., Ma, W., Lawrence, D. & Lee, T.C. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 139, 591-599 (2011).
30. Tsai, S.T. et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin. Ther. 29, 1027-1039 (2007).
31. Garza, D., Murphy, M., Tseng, L.J., Riordan, H.J. & Chatterjee, A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol. Psychiatry 69, 1075-1082 (2011).
32. Niaura, R. et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: A randomized controlled trial. Curr. Med. Res. Opin. 24, 1931-1941 (2008).
33. Oncken, C. et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 166, 1571-1577 (2006).
34. Tonstad, S., Tønnesen, P., Hajek, P., Williams, K.E., Billing, C.B. & Reeves, K.R.; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 296, 64-71 (2006).
35. Wang, C., Xiao, D., Chan, K.P., Pothirat, C., Garza, D. & Davies, S. Varenicline for smoking cessation: A placebo-controlled, randomized study. Respirology 14, 384-392 (2009).
36. Bolliger, C.T. et al. Effects of varenicline in adult smokers: A multinational, 24-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 33, 465-477 (2011).
37. World Medical Association. World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. (2008). Accessed 31 October 2012.
38. International Conference on Harmonisation. The ICH Process for Harmonisation of Guidelines. (2009). Accessed 31 October 2012.
39. Osman, A., Bagge, C.L., Gutierrez, P.M., Konick, L.C., Kopper, B.A. & Barrios, F.X. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): Validation with clinical and nonclinical samples. Assessment 8, 443-454 (2001).